AJCN endorses Sirco

Provexis PLC
16 May 2006


                                  PROVEXIS PLC

                         ('Provexis' or the 'Company')

         SircoTM science to be published in leading scientific journal

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces a major international scientific
endorsement for its lead product SircoTM. Two scientific papers, which detail
the clinical efficacy of SircoTM, are to be published by the American Journal of
Clinical Nutrition (AJCN). The AJCN is internationally recognised as the
highest-ranked peer-reviewed journal in the nutrition field.

SircoTM, a chilled fruit juice, is the first heart health product to contain the
patented FruitflowTM technology. FruitflowTM is a natural bioactive extract from
tomato that works by reducing blood platelet aggregation within hours of
consumption. Platelet aggregation plays a significant role in the formation of a
thrombus (internal blood clot) which can cause a heart attack or stroke.

SircoTM is currently available in the UK in the chilled juice category in over
550 Tesco and Waitrose stores. The product is targeted at adults who are keen to
maintain cardiovascular health.

Commenting on the news of the acceptance by the journal, Dr Stephen Franklin,
CEO of Provexis, said:

'We are delighted that the science behind FruitflowTM has been accepted for
publication by the highest-ranked peer-reviewed scientific journal in the field.
We have remained resolute in our belief that the FruitflowTM technology is
world-class and that this would be recognised by the most stringent scientific
review process in the field of clinical nutrition.'

'The acceptance of two separate scientific papers, published in this
internationally accredited journal is a significant milestone for the Company
and an essential precursor to initiating a number of key commercial activities'.


For further information please contact:

Provexis plc
Dr Stephen Franklin                             020 8392 6631

Bell Pottinger Corporate & Financial
Emma Kent                                       020 7861 3232










                      This information is provided by RNS
            The company news service from the London Stock Exchange